Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers

SIMPLE SUMMARY: Targeted therapies are increasingly used in patients with early breast cancer and a high clinical risk of relapse. Patients with clinical high-risk HER2-negative early breast cancer might be eligible for olaparib treatment. A prerequisite for olaparib treatment is a germline BRCA1/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Dannehl, Dominik, Engler, Tobias, Volmer, Léa Louise, Tegeler, Christian Martin, Fusshoeller, Julia, Gabrysch, Emma, Eissler, Kenneth, Seller, Anna, Grischke, Eva-Maria, Hahn, Markus, Gruber, Ines, Schochter, Fabienne, Pfister, Kerstin, Veselinovic, Kristina, Leinert, Elena, Rack, Brigitte, Fink, Visnja, Janni, Wolfgang, Brucker, Sara Yvonne, Hartkopf, Andreas Daniel, Schäffler, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417328/
https://www.ncbi.nlm.nih.gov/pubmed/37568663
http://dx.doi.org/10.3390/cancers15153847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417328/
https://www.ncbi.nlm.nih.gov/pubmed/37568663
http://dx.doi.org/10.3390/cancers15153847

Ejemplares similares